Veterinary oncology could be moving closer to a more differentiated treatment market after Merck Animal Health published peer-reviewed clinical findings on gilvetmab, its caninized anti-PD-1 monoclonal antibody for dogs with melanoma or mast cell tumour. The update matters commercially because it adds published clinical evidence to a product category that has historically had few targeted options in companion-animal practice.

The company said on 1 October that two studies had appeared in the Journal of Veterinary Internal Medicine and the Journal of the American Veterinary Medical Association. Gilvetmab is conditionally approved by the US Department of Agriculture for dogs with melanoma or mast cell tumour and is currently available only in the United States. Conditional licensing means that safety, efficacy and potency have not yet been fully evaluated, while further studies continue.

Across the evaluated dogs with melanoma or mast cell tumour, the reported clinical benefit rate - complete response, partial response or stable disease - was 66.7%. In stage II and III oral malignant melanoma, the reported objective response rate was 20%, with 40% of dogs maintaining stable disease. For stage I to III mast cell tumours, Merck reported a 46% objective response rate and said median time to progression had not been reached during the study window.

The data also address a practical consideration for referral practices and pet owners. The treatment was administered as a 30-minute intravenous infusion after diphenhydramine premedication; 96% of canine patients maintained a high quality of life during therapy, while serious adverse events were reported as uncommon at 5.9%. Those figures do not establish a final safety profile, but they give veterinary oncologists a more concrete basis for discussing a targeted immunotherapy with clients.

For the animal-health market, the significance is broader than one medicine. Published evidence can support specialist adoption, referral-centre protocols and investment in companion-animal oncology services, while the conditional pathway preserves the need for post-market evidence. The commercial opportunity will depend on continued clinical confirmation, pricing and the ability of practices to incorporate infusion-based treatment into care pathways. Merck's release places those questions in a more evidence-led setting rather than treating canine checkpoint inhibition as a purely experimental concept.

For more information: Merck Animal Health